Benefits
Occasional constipation
In one double-blind trial of 60 adults (95% men) with occasional constipation, a nightly capsule with 86 mg Gingever (12 mg gingerols) for 8 weeks improved constipation symptom and quality-of-life scores and weekly stool frequency versus placebo, and raised stool secretory IgA. Stool consistency, fecal short-chain fatty acids, TNF-alpha and IL-6 did not differ from placebo. This is a small trial funded by OmniActive in a journal not indexed in PubMed.
Ginger class evidence — Nausea relief
Class evidence for generic ginger: a review of clinical trials found that divided daily doses totaling 1,500 mg helped relieve nausea; evidence for post-operative and motion sickness is less certain. ACOG lists ginger as a nonpharmacologic option that may be considered for pregnancy nausea, not as a first-line drug treatment. Gingever itself has not been tested for nausea, so it is unproven that its lower mg dose matches the generic ginger doses used in these trials.
Inflammation markers: generic ginger data, not this brand
This evidence is for generic ginger, not Gingever. In a placebo-controlled trial of 120 people with knee osteoarthritis, 500 mg/day generic ginger powder for 3 months lowered blood TNF-alpha and IL-1beta. For Gingever itself, the only positive inflammation data come from a study in rats with induced arthritis, and in its one human trial (a constipation study) blood TNF-alpha and IL-6 did not change versus placebo.
Gut microbiome shifts in one trial
Recent research positions 6-gingerol as a 'potential prebiotic' that modulates gut microbiome composition. Ginger juice has been shown to affect bacterial diversity with sex-based response differences. In the Gingever constipation trial some bacterial groups shifted in the ginger group but not the placebo group, overall diversity did not change, the authors report lower levels of some butyrate-producing genera, and fecal short-chain fatty acids did not differ from placebo.
Supercritical CO₂ extraction quality
Solvent-free CO₂ extraction process avoids residual organic solvents found in some hexane or ethanol-extracted botanicals. Cleaner extraction profile preserves the full phytochemical complement (gingerols, shogaols, zingerone, volatile oils) without thermal degradation that can occur in hot-extraction methods.
Convenience and formulation flexibility
Low-dose ginger advantage: capsules, gummies, beverages, and bars can deliver therapeutic gingerol content without the bulky 1-2 g ginger powder dose. This makes it practical to combine ginger with other actives in small dosage forms. Self-affirmed GRAS status supports wide application.
Mechanism of action
5-HT3 serotonin receptor antagonism
In lab and animal studies, gingerols block serotonin 5-HT3 receptors in the gut, a target shared with some prescription anti-nausea drugs. This may help explain ginger's anti-nausea effects in human trials, but it has not been measured in people taking Gingever.
Gastric motility enhancement
In a small crossover study of 11 people with functional dyspepsia, a single 1.2 g dose of generic ginger sped gastric emptying, though digestive symptoms did not differ from placebo. Mechanism involves modulation of cholinergic and serotonergic motility pathways.
COX-2 and 5-LOX inflammation pathway inhibition
Gingerols inhibit cyclooxygenase-2 (COX-2) and 5-lipoxygenase (5-LOX) — both major inflammatory enzymes. These enzyme effects come mainly from lab studies and may help explain the modest joint and muscle effects seen in trials of generic ginger.
Prebiotic-like microbiome modulation
Lab research suggests 6-gingerol may shift gut bacteria. In the Gingever constipation trial some bacterial groups changed in the ginger group, but fecal short-chain fatty acids did not differ from placebo and the authors report lower levels of some butyrate-producing genera, so a prebiotic effect has not been shown.
Clinical trials
Randomized double-blind parallel placebo-controlled trial in 60 adults with occasional constipation. Intervention: one 280 mg capsule nightly after dinner for 8 weeks, containing 86 mg Gingever (12 mg gingerols) plus cellulose, or a cellulose placebo. Funded by OmniActive.
60 adults with occasional constipation
Randomized double-blind parallel placebo-controlled trial in 60 adults with occasional constipation. Intervention: 86 mg Gingever (12 mg gingerols) in a 280 mg capsule, or cellulose placebo, nightly for 8 weeks; 55 of 60 completed. Versus placebo: better PAC-SYM and PAC-QoL scores at days 28 and 56, more stools per week at days 14, 28 and 56, and higher stool secretory IgA at day 56. No difference versus placebo in Bristol stool consistency, stool beta-defensin 2, blood TNF-alpha or IL-6, or fecal short-chain fatty acids. Funded by OmniActive. Published in J Nutr Health Sci 2023;10(1):104, not indexed in PubMed; registered CTRI/2022/01/039843.
Evidence review of clinical trials evaluating ginger for various gastrointestinal disorders. Strongest evidence: divided lower daily doses (1,500 mg/day total) effective for nausea relief.
People in clinical trials of generic ginger for nausea and other gastrointestinal complaints.
Evidence review of clinical trials evaluating ginger for various gastrointestinal disorders. Strongest evidence: divided lower daily doses (1,500 mg/day total) effective for nausea relief. For other gastrointestinal disorders the authors found too few trials to show clear results, and they called for dose-finding studies of ginger and standardized extracts. This review covers generic ginger and does not include Gingever.